Audit: QRS - Red Spinach Extract for Health & Longevity
Audit conducted on 16/08/2026 04:10 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated variable against the ER: protocol cells vs ER lines 341/345/367, time cells vs lines 351/400, benefit and risk tiers vs the ER Expected Benefits / Potential Risks & Side Effects headings, gates vs lines 292-319, monitoring table vs lines 430-436, cadence vs line 426, qualitative items vs lines 440-445. All literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedged ER wording is carried through: No established target; track change from the individual's own baseline (marker_5_target, ER line 434), Addresses the unverified oxalate content of amaranth-derived material (marker_7_why, ER line 436), Screens the theoretical iodide-competition effect (marker_6_why, ER line 435), and the at-a-glance Evidence for this extract is thin and pulls both ways (ER line 471). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening. Contraindications keep the ER’s absolute framing (Pregnancy and lactation, Infants under 6 months); action_3_sub keeps the ER’s dropped entirely during use (ER line 367). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories are preserved. All 6 stop_items come from the ER’s Populations who should avoid list (lines 314-319); all 9 caution_items come from the ER Key Interactions & Contraindications bullets (lines 292-310). Nothing from Benefit-Modifying Factors or Risk-Modifying Factors is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, study citations, author names, NCT identifiers, or brand names (OxyStorm / VitaSpinach) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The QRS mirrors the ER’s measured, conflict-acknowledging register (ER Conclusion, lines 469-475). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (nitrate percentages, mmHg and mmol/L targets) while remaining accessible; the extract’s genuine uncertainty is presented without discouraging framing. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as evidence and observed practice (Trials dosed 40-75 minutes ahead, Pooled performance effects concentrated with...) rather than as instructions from a clinician. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives or clinical directives; monitoring targets and cadence are stated as ranges and schedules taken from the ER. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of recommend, advise, or guidance in the document’s voice; every cell is declarative. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears anywhere in the QRS (verified across the whole file). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; the ER’s TSH is expanded to Thyroid-stimulating hormone (marker_6_name) using the ER’s own definition at line 435. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every field is a condensed phrase or a one-to-two-sentence sub-line; the ER’s 14 protocol bullets reduce to 3 cells and the 10 interaction bullets to 9 short items. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address; confirmed no you / your in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a proactive, risk-aware reader: dose thresholds, orthostatic checks, and a nitrite-conversion marker are all surfaced. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Effortful items are retained: dropping mouthwash entirely, 2-3 hour pre-session timing, daily home blood-pressure logging, 24-hour urinary oxalate collection. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nothing is simplified to general-population level; the sheet keeps eGFR staging, mmol/L potassium targets, and the salivary nitrite conversion check. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance explicitly flags that commercial servings sit under the dose linked to benefit, which is the decision-relevant signal for this audience (ER lines 471, 402). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of anti-aging anywhere in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (methaemoglobinaemia, orthostatic, gastrointestinal discomfort, vasodilation); no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed labels are present verbatim: Protocol (line 446), Time to effect (492), Benefits (542), Risk & Side Effects (617), Monitoring (640), Qualitative Assessment (758), Contraindications (571), Key Interactions (584), tier labels High/Medium/Low/Speculative, and the Marker / Target / Why column headers (644-646). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 distinct data-qrs-var names from the template are present; the repeatable marker_#_* and qualitative_item_# patterns are instantiated as marker_1..7 and qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows no change outside the variable regions; the non-variable spans website="evidence_review", website="audit", and website="full_review" are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relied on by the QRS is empty; every mapped ER section (Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring Protocol) carries content, so no empty-state phrasing applies. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels are reused verbatim where they exist: Standard dose (ER line 341), Timing before exercise (345), Oral hygiene protocol (367), Loading period (351). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No paraphrased or invented labels. The two time labels without a matching ER bold label, Vascular and performance effects and Sustained blood-pressure change, are lifted from the ER’s own Time to effect sentence at line 400; monitoring marker names match the ER biomarker table (lines 430-436). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file; the ER’s tier emoji and the Conflicted warning glyphs are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to the per-section budget rather than extended: 14 ER protocol bullets to 3 cells, 10 interaction bullets to 9 short items with mechanistic clauses stripped, and 5 low-tier risks collapsed to a single semicolon-separated line. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens on line 2, immediately after <!doctype html> on line 1, and precedes all other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens with --- on line 3 and closes with --- on line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block sits inside an HTML comment (lines 2-14) and is not echoed by any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed and unquoted except duration: "00:03", which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: red_spinach_extract_2026-0825-0138_Opus_ER.md, matching the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0401, in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Opus is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5 is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: red_spinach_extract_2026-0825-0138_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Verified again across all nine keys: no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Red Spinach Extract for Health & Longevity - Quick Reference Sheet, matching canonical_topic with & entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Red Spinach Extract for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/16/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0816-0401. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the template’s title and subline; no badge, AKA line, audit date, or variant marker was added. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 469-471) into the decision-relevant core: what the extract is, that precursor availability rises, and that everything downstream is unsettled because of dose. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Mechanism and widens blood vessels from ER line 469; raises the body's nitrate supply / much less settled from line 469; thin and pulls both ways and the dose explanation from line 471. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; nitric oxide is glossed inline as the signal that widens blood vessels, and no technical classification is used unexplained. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks, or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER’s Populations who should avoid Red Spinach Extract list inside Key Interactions & Contraindications (lines 312-319). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 6 ER contraindications are represented, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | All 6 items are individual <li> elements inside the stop_items span (lines 574-579). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale clauses are stripped: for whom nitrate is a documented methaemoglobinaemia hazard, where nitrate clearance and potassium handling are both impaired, and where no safety data at supplemental nitrate doses exist are all removed. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and staging are preserved: below 100 mmHg, under 6 months, stage 4 or worse (eGFR below 30 mL/min/1.73 m2). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated because the ER does identify populations that should avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Contraindications section is not empty (6 items). |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER Key Interactions & Contraindications bullets (lines 292-310). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | 9 of the ER’s 10 interaction bullets are carried; Organic nitrates and nitrites is correctly excluded because it is already a contraindication (Organic nitrate medication for angina or heart failure). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | All 9 items are individual <li> elements inside the caution_items span (lines 587-607). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity tags and mechanistic sentences are stripped; e.g. the ER’s which relax vessels, which relax artery walls, and which increase urine output glosses are removed from the antihypertensives item, and no Severity - ... clause survives. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists are preserved in condensed form: (sildenafil, tadalafil, vardenafil), (lisinopril, losartan, amlodipine, thiazide diuretics), (ACE inhibitors, angiotensin receptor blockers, spironolactone), (omeprazole, esomeprazole, calcium carbonate), (beetroot powder, arugula or celery concentrates, other amaranth extracts), (L-Citrulline, L-Arginine, aged garlic extract, hibiscus, magnesium, high-dose omega-3), (sauna, hot baths, alcohol, post-exercise recovery). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated because the ER identifies ten interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Key Interactions section is not empty (9 items). |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action cells trace to the ER Therapeutic Protocol section (lines 341, 345, 367). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, pre-exercise timing, and the oral hygiene protocol are the three implementation aspects the ER treats as decisive; the ER states that without the tongue bacteria dose and timing are irrelevant (line 367). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section lists 14 bullets, far more than three actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields carry ER-derived content: Standard dose / 1-2 g, Timing before exercise / 2-3 hours, Oral hygiene protocol / No mouthwash, each with an ER-sourced sub-line. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Acute onset (ER line 400), the >3-day loading requirement (line 351), and the 2-4 week window for sustained blood-pressure change (line 400) are the three time-to-effect aspects the ER supplies. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three map to the ER’s medium-tier benefits (aerobic efficiency / exercise tolerance and blood-pressure reduction); within that tier the ordering runs from the acute performance effect through the loading requirement to the slowest endpoint. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields are populated from the ER: 1-3 hours, > 3 days, 2-4 weeks, each with an ER-sourced sub-line. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations line 400, Therapeutic Protocol line 351), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers mirror the ER Expected Benefits headings (lines 148-192). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated (lines 544-564). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are reduced to the ER benefit headings alone; magnitudes, mechanisms, and the Conflicted qualifiers are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers (high, medium, low, speculative) carry items in the ER Expected Benefits section. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers mirror the ER Potential Risks & Side Effects headings (lines 220-272). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated (lines 619-634). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are reduced to the ER risk headings; the five low-tier risks are joined by semicolons with no magnitudes or mechanisms. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers (high, medium, low, speculative) carry items in the ER Potential Risks & Side Effects section. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success biomarker table (lines 428-436). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 ER biomarkers are listed with their optimal ranges and rationale: resting blood pressure, orthostatic change, serum potassium, eGFR, plasma or salivary nitrite, thyroid-stimulating hormone, 24-hour urinary oxalate. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from ER line 426: daily home blood pressure for two weeks then weekly, potassium and kidney filtration at 6 weeks then every 6-12 months, TSH annually only with existing thyroid disease. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (lines 440-445). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 ER qualitative markers are listed verbatim. |
Issues 16/08/2026 04:10
Pass rate 100.00%. No issues found.